These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine. Dhall G; Finlay JL; Dunkel IJ; Ettinger LJ; Kellie SJ; Allen JC; Egeler RM; Arceci RJ Pediatr Blood Cancer; 2008 Jan; 50(1):72-9. PubMed ID: 17455311 [TBL] [Abstract][Full Text] [Related]
5. Outcome of pediatric patients with Langerhans cell histiocytosis treated with 2 chlorodeoxyadenosine: a nationwide survey in Japan. Imamura T; Sato T; Shiota Y; Kanegane H; Kudo K; Nakagawa S; Nakadate H; Tauchi H; Kamizono J; Morimoto A Int J Hematol; 2010 May; 91(4):646-51. PubMed ID: 20361277 [TBL] [Abstract][Full Text] [Related]
6. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: Results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study. Morimoto A; Ikushima S; Kinugawa N; Ishii E; Kohdera U; Sako M; Fujimoto J; Bessho F; Horibe K; Tsunematsu Y; Imashuku S; Cancer; 2006 Aug; 107(3):613-9. PubMed ID: 16804933 [TBL] [Abstract][Full Text] [Related]
8. Activity and toxicity of 2-CDA in Langerhans cell histiocytosis: a single institutional experience. Biswas G; Khadwal A; Arora B; Bhagwat R; Banavali SD; Nair CN; Pai SK; Kurkure PA; Parikh PM Indian J Cancer; 2007; 44(4):137-41. PubMed ID: 18322355 [TBL] [Abstract][Full Text] [Related]
9. A phase II trial using thalidomide for Langerhans cell histiocytosis. McClain KL; Kozinetz CA Pediatr Blood Cancer; 2007 Jan; 48(1):44-9. PubMed ID: 16333818 [TBL] [Abstract][Full Text] [Related]
10. Response to initial treatment of multisystem Langerhans cell histiocytosis: an important prognostic indicator. Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H; Med Pediatr Oncol; 2002 Dec; 39(6):581-5. PubMed ID: 12376981 [TBL] [Abstract][Full Text] [Related]
11. Pulmonary Langerhans cell histiocytosis: a variable disease in childhood. Odame I; Li P; Lau L; Doda W; Noseworthy M; Babyn P; Weitzman S Pediatr Blood Cancer; 2006 Dec; 47(7):889-93. PubMed ID: 16276522 [TBL] [Abstract][Full Text] [Related]
12. Craniospinal Langerhans cell histiocytosis in children: 30 years' experience at a single institution. Davidson L; McComb JG; Bowen I; Krieger MD J Neurosurg Pediatr; 2008 Mar; 1(3):187-95. PubMed ID: 18352762 [TBL] [Abstract][Full Text] [Related]
13. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Bernard F; Thomas C; Bertrand Y; Munzer M; Landman Parker J; Ouache M; Colin VM; Perel Y; Chastagner P; Vermylen C; Donadieu J Eur J Cancer; 2005 Nov; 41(17):2682-9. PubMed ID: 16291085 [TBL] [Abstract][Full Text] [Related]
14. [Langerhans cell histiocytosis in adult patients--a disease with many faces. Experience of a centre and an overview of the disease symptoms]. Adam Z; Pour L; Krejcí M; Neubauer J; Vanícek J; Vasků V; Hájek R Vnitr Lek; 2008 Nov; 54(11):1063-80. PubMed ID: 19069680 [TBL] [Abstract][Full Text] [Related]
15. Langerhans' cell histiocytosis in adults: a clinical and therapeutic analysis of 11 patients from a single institution. Giona F; Caruso R; Testi AM; Moleti ML; Malagnino F; Martelli M; Ruco L; Giannetti GP; Annibali S; Mandelli F Cancer; 1997 Nov; 80(9):1786-91. PubMed ID: 9351548 [TBL] [Abstract][Full Text] [Related]